Hypertension is a common condition, which, depending on its definition, affects 10-25% of the population. Because it is an established risk factor for coronary and cerebrovascular disease, hypertension has, quite rightly, been targeted as an important factor in determining the health of the nation. Despite this we can explain the underlying cause of a patient's hypertension in Ͻ5% of cases; the remainder are labelled 'essential' hypertension, an elegant way of stating that the aetiology is unknown. As a result, in the vast majority of cases treatment is given on an empirical basis.
mary aldosteronism due to an adrenocortical tumour (Conn's Syndrome). 1 Both subjects had a mineralocorticoid excess syndrome, characterised by potassium deficiency, suppressed plasma renin activity (PRA) and increased aldosterone secretion rate, which, in contrast to tumorous aldosteronism, responded to treatment with the synthetic glucocorticoid, dexamethasone. Shortly afterwards, an additional, well-documented case was described, confirming the existence of this new 'glucocorticoid remediable' aldosteronism syndrome. 2 Subsequently it was shown to be inherited in an autosomal dominant fashion and approximately 100 cases were reported in the world literature up to the early 1990's. [3] [4] [5] [6] [7] [8] [9] The most common presentation of GRA used to be the discovery of asymptomatic severe hypertension, especially in infancy or early adulthood. With the ability to identify individuals by genetic or biochemical testing, much milder or earlier clinical forms are being described. A strong family history of hypertension, often associated with premature death due to cerebrovascular accident is characteristically seen in some GRA kindreds. 10 In some cases control of blood pressure (BP) has been unsatisfactory with common antihypertensive agents. Routine biochemistry may reveal hypokalaemia, which is often severe if patients are taking potassium-wasting diuretics. However, the clinical spectrum of this disorder is heterogeneous, with up to 50% of all cases having normal serum potassium levels, and others having apparently 'normal' BP. 4, 7, 10 In GRA, the renin-angiotensin system is suppressed; aldosterone levels are either elevated or normal and is exclusively regulated by ACTH, rather than the normal principal secretogogue, angiotensin II. As a result, plasma aldosterone levels do not increase and plasma renin activity (PRA) remains suppressed in response to upright posture or to an infusion of angiotensin II. 6, 8, [11] [12] [13] [14] In establishing the differential diagnosis of primary aldosteronism, patients should have supine PRA, aldosterone and cortisol measured at 08.00 h and again erect at 12.00 h. A fall in plasma cortisol (and by inference ACTH) together with a concomitant fall in plasma aldosterone across the same period is highly suggestive of GRA. A single measurement may not be representative, and this procedure should be repeated on at least two occasions. In addition, the administration of ACTH (Synacthen, Ciba-Geigy) to patients with GRA results in aldosterone hyper-responsiveness compared to normal subjects 12, 13 and is sustained as long as ACTH is infused.
14 Adrenal computerised tomography is usually normal in patients with GRA though Pascoe et al 15 have described a French family with seven affected members, two of which had adrenal masses and another two adrenal hyperplasia on CT. Further information is required on the morphology of the adrenals in GRA since most cases are treated medically and the adrenals are not removed.
There are two important consequences of the regulation of aldosterone production solely by ACTH. Firstly, there is dysregulation of aldosterone secretion because there is no negative feedback loop; aldosterone does not suppress ACTH secretion from the pituitary. Secondly, the exogenous administration of a glucocorticoid such as dexamethasone, by decreasing the secretion of ACTH, results in a profound suppression of aldosterone levels, a concomitant natriuresis, and correction of the biochemical and hormonal abnormalities seen in this disorder. Prolonged treatment with glucocorticoids leads to reactivation of the renin-angiotensin system and restoration of the normal regulation of aldosterone secretion. 16 However, careful examination of aldosterone regulation in chronically treated individuals suggests that aldosterone secretion may remain relatively insensitive to angiotensin, compared with ACTH (Stowasser and Gordon, personal communication).
A further characteristic feature of GRA is the production of large quantities of the normally rare, 18-hydroxylated steroids, 18 hydroxy-cortisol and corticosterone (18-OHF, 18-OHB) and 18 oxo-cortisol and corticosterone (18-OXOF, 18-OXOB). [17] [18] [19] This abnormal pattern of corticosteroid biosynthesis was an important observation, providing a sensitive diagnostic test for patients with GRA (plasma and/or urinary assays), but also providing further insights into the pathogenesis of the condition. The synthesis of these steroids requires the simultaneous presence of two enzymes, 17␣-hydroxylase and 18-hydroxylase/oxidase. 17␣-hydroxylase is required for normal glucocorticoid biosynthesis and is expressed in the zona fasciculata/reticularis, whilst the combined 18-hydroxylation/oxidation step is the final pathway for aldosterone synthesis and as such would be predicted to be localised in the normal adrenal only to the zona glomerulosa. However, like aldosterone itself, these 18-hydroxylated steroids were also shown to be ACTH-regulated and suppressed by dexamethasone, suggesting aberrant expression and regulation of 18-hydroxylase in GRA. 17, 18 The molecular basis for GRA was first identified by Lifton and colleagues in 1992, 20, 21 following the cloning and characterisation of the P450 11␤-hydroxylase genes involved in the final pathways of glucocorticoid and mineralocorticoid biosynthesis 22, 23 ( Figure 1 ). 11␤-hydroxylase (CYP11B1) is responsible for the conversion of 11-deoxycortisol to cortisol and, as such is regulated by ACTH. In contrast, aldosterone synthase (CYP11B2) mediates 11␤-hydroxylation, 18-hydroxylation and 18-oxidation of 11-deoxycorticosterone to aldosterone and is regulated by angiotensin II. 24 CYP11B2 is expressed only in the zona glomerulosa of the adrenal gland, defining the functional zonation of aldosterone secretion within the adrenal. The two genes are found in close proximity on human chromosome 8, are 95% homologous in nucleotide sequence, and have identical intron-exon structure. 22, 23 GRA is presumed to result from the production of a chimeric gene formed due to unequal cross-over and genetic recombination at meiosis. Such a CYP11B1/ CYP11B2 hybrid gene contains 3Ј sequences of aldosterone synthase and 5Ј sequences of 11␤-hydroxylase. So long as the breakpoint of the hybrid gene is in or 5Ј to exon 4, the resultant protein can synthesise aldosterone but is under the regulatory control by ACTH, explaining the phenotype of GRA. 20, 21, 25 In an adrenal gland removed from an affected case of GRA, this chimeric gene was indeed shown to be expressed throughout the adrenal cortex and was stimulated by ACTH in vitro. 15 This abnormal gene duplication can be detected by Southern blotting, 26 or by faster and cheaper long polymerase chain reaction (PCR) 27 allowing for direct genetic screening for this disorder and prenatal diagnosis. Hypertensive patients with primary aldosteronism without demonstrable adenomata, as well as those with suppressed levels of PRA (especially children and young adults with positive family history of hypertension/CVA), are candidates who should be screened. Although the condition is inherited as an autosomal dominant trait, BP is reported to be higher in offspring inheriting GRA from the mother compared to the father. 28 It is possible that the higher aldosterone levels in pregnancy in the former scenario results in 'programming' of hypertension in the developing fetus. Figure 1 Adrenal steroidogenesis outlining the pathogenesis of GRA. In GRA a chimaeric gene is expressed in the zona fasciculata containing 5Ј sequences of CYP11␤1 and 3Ј sequences of CYP11␤2. As a result this gene product will synthesize aldosterone (square box) but is under the control of ACTH.
Theoretically, the suppression of ACTH with exogenous glucocorticoids should correct all of the abnormalities of GRA, but this treatment is complicated by untoward complications in some patients due to glucocorticoid excess, notably a reduction in growth rate in children. Treatment with the smallest effective dose of shorter-acting glucocorticoids, such as prednisolone or hydrocortisone, may be effective and reduce the risk of complications, especially in children. 9, 16, 29 A further concern with glucocorticoid treatment is that patients may undergo a brief period of mineralocorticoid insufficiency following the initiation of therapy before the renin-angiotensin axis recovers. Finally, as with any secondary cause of hypertension, removing or treating the cause may not totally normalise BP.
Alternative treatment modalities include mineralocorticoid receptor blockade with spironolactone or inhibition of the mineralocorticoid-sensitive distal tubule sodium channel with amiloride.
Liddle's syndrome
In 1963 Grant Liddle described a family comprising multiple siblings with early onset hypertension and hypokalaemia. Affected cases were subsequently shown to have suppressed renin activity in keeping with a mineralocorticoid-excess state, but aldosterone levels were also suppressed. 30 BP and hypokaelaemia was largely unaffected following treatment with mineralocorticoid receptor (MR) antagonists such as spironolactone, but responded well to triamterene, an inhibitor of epithelial sodium transport. 31, 32 Furthermore in the proband of one of Liddle's original cases, renal transplantation resulted in restoration of normotension and normokalaemia arguing against a circulating mineralocorticoid. 33 A more generalised defect in Na transport was suggested with the observation of defective Na transport in erythrocytes from affected cases. 34 With our improved understanding of mineralocorticoid hormone action, the molecular basis for Liddle's syndrome has been explained. Mineralocorticoid-regulated epithelial sodium transport is principally dependent upon the activity of two sodium pumps, the basolateral Na/K ATPase and the apical sodium channel. The epithelial sodium channel in the rat and human have recently been cloned and characterised. The ␣-subunit of this channel supports only low levels of amiloride-sensitive sodium conductance in isolation. The ␤-and ␥-subunits do not induce sodium conductance when expressed alone, but greatly augment sodium conductance when transfected with the ␣-subunit. Thus full sodium transport requires the concerted action of all three subunits of the apical Na channel. Liddle's syndrome could be explained on the basis of enhanced sodium reabsorption in the distal nephron and distal colon. One obvious candidate gene was the apical Na channel. The ␤-and ␥-subunits lie in close proximity on chromosome 16p and mutations in both the ␤-or ␥-subunits have been described in affected cases. 35, 36 In each case these mutations cause deletions (45-75 aa) of the C-terminal portions of the subunit proteins producing a Na channel which is constitutively active. How this positive effect is mediated is uncertain, but it may result from induction of synthesis of new sodium channels. 37 The syndrome of apparent mineralocorticoid excess (AME) First described in the 1970's by Stanley Ulick and Maria New, 38 this is an autosomal recessive form of hypertension, predominantly found in children characterised by hypokalaemia with suppression of renin and aldosterone values. 39 In contrast to Liddle's syndrome, however, the condition does respond to MR antagonists, albeit in high doses. The mineralocorticoid excess is severe with several reported fatalities from vascular events and hypokalaemia. The condition is associated with a defect in the peripheral metabolism of cortisol to hormonally inactive cortisone. [38] [39] [40] [41] [42] [43] [44] This reaction is catalysed by an enzyme complex, 11␤-hydroxysteroid dehydrogenase and an assessment of its activity in vivo can be inferred from urinary cortisol metabolite studies (showing an increase in the urinary ratio of tetrahydrocortisols (THF, allo-THF) to tetrahydrocortisone (THE)) or cortisol half-life studies. The normal urinary THF+allo-THF/THE ratio is approximately 1 but this ratio is grossly elevated in AME at Ͼ10; plasma cortisol half-life is in excess of 120 min (normal 60-90 min). Despite this prolonged cortisol half-life, patients with AME have normal circulating cortisol levels due to a concomitant fall in daily cortisol secretion, mediated by the negative feedback mechanism. Groups had searched extensively for unidentified circulating mineralocorticoids before it was appreciated that the implicated mineralocorticoid in AME was cortisol itself. 44, 45 Liquorice, of which the active principal is glycyrrhetinic acid, together with its synthetic derivative carbenoxolone had been known to act as mineralocorticoids for several years. It was subsequently shown that these compounds exert their mineralocorticoid effects, not directly, but by inhibiting 11␤-HSD, [46] [47] [48] [49] resulting in an acquired form of AME. Two questions remained; how did cortisol act as a mineralocorticoid and what was the molecular basis for AME?
The cDNA encoding the human MR was subsequently isolated. 50 When this was transfected into COS cells it was found to have the same inherent affinity for mineralocorticoid (aldo) and glucocorticoids (cortisol, corticosterone), confirming earlier in vitro studies. 51 Faced with circulating concentrations of cortisol some 1000-fold those of aldo, how did aldo get access to the MR in vivo? Why wasn't the MR swamped with cortisol? AME had provided us with a unique experiment of biology; here was an example of severe mineralocorticoid excess caused by cortisol itself, suggesting that 11␤-HSD may play a crucial role in normal physiology in dictating MR specificity. Subsequently this was shown to be the case; 11␤-HSD inactivates cortisol to cortisone in the mineralocorticoid target tissues, kidney, colon and salivary gland permitting aldo to interact with the MR. 52, 53 In AME or following liquorice ingestion, this does not occur and cortisol can then act as a potent mineralocorticoid. After a series of physiological and enzymatic studies from several laboratories, two human 11␤-HSD isoforms have been cloned and characterised. [54] [55] [56] [57] [58] It is the NAD-dependent type 2 isozyme which protects the MR in an autocrine fashion and mutations in the gene encoding this enzyme on chromosome 16q22 explain AME. [59] [60] [61] Mutations have tended to cluster to exons III-V and result in proteins with severely attenuated or absent activity. 62 Thus three distinct causes of monogenic hypertension have been described in the last 5 years all of which result in the same phenotype, mineralocorticoid hypertension (Figure 2 ). Is this pure serendipity or does it have implications for patients with essential hypertension? The prevalence of GRA, Liddle's and AME in patients labelled as having essential hypertension is unknown. It is true that additional cases have been reported since the elucidation of the molecular basis of these conditions. [62] [63] [64] However, when hospital hypertension clinics have been screened, certainly for GRA, very few if any cases have been detected (Professor J Connell, personal communication). Whilst it seems likely that these conditions will remain rare causes of hypertension, their detection may be difficult. Hypokalaemia is one obvious screening test, but it is now appreciated that up to 50% cases of genetically proven cases of GRA 64 and Liddle's syndrome 35, 36 are normokalaemic and the absence of hypokalaemia does not exclude these conditions. A similar argument applies for the detection of primary aldosteronism. 65 Until the true prevalence of these conditions in hypertensive patients is defined, the authors suggest a low threshold for investigating patients with renin, aldosterone and cortisol metabolite measurements. At risk groups would include any patient with a family history of hypertension.
Figure 2
Summary of the three causes of monogenic mineralocorticoid hypertension described to date. A schematic diagram representing an epithelial cell in the distal colon or distal nephron is shown. In normal physiology aldosterone interacts with the mineralocorticoid receptor (MR) to stimulate sodium reabsorption via induction of the apical Na channel and serosal Na/K ATPase pump. GSH (glucocorticoid-suppressible hyperaldosteronism) is a cause of aldosterone excess, whilst AME results in mineralocorticoid excess because cortisol cannot be inactivated to cortisone by the type 2 isoform of 11␤-hydroxysteroid dehydrogenase 11␤-HSD) and acts on the MR. Finally Liddle's syndrome occurs because of constitutively active mutations in the ␤ and ␥-subunits of the apical Na channel.
Is it possible that more subtle defects in the activity of 11␤-hydroxylase, the apical Na channel and 11␤-HSD2 may be implicated in the pathogenesis of essential hypertension? There are data to suggest defective 11␤-HSD 66, 67 and 11␤-hydroxylase 68 in some hypertensive individuals, and genetic linkage studies in affected siblings or multiplex families with hypertension are underway using these candidate genes. Nevertheless these clinical observations on patients with relatively rare causes of hypertension have provided the molecular geneticist with important candidate genes which may convey susceptibility to the development of essential hypertension. Finally this renewed interest in steroids and hypertension has led to a better understanding of the underlying mechanisms. We have always considered 'mineralocorticoid-based' hypertension to be predominantly volume-mediated; the enhanced renal sodium reabsorption causing an expanded extracellular volume. 44, 69 Whilst this is still the case, it is now also clear that mineralocorticoids can raise BP through actions within the central nervous system 70 and directly at the level of the vasculature. 71, 72 Furthermore the notion that corticosteroids may 'programme' hypertension in the developing fetus 73 is an exciting hypothesis under active scrutiny. In summary and to quote Richard Gordon, 65 'thanks to clinical curiosity, biochemical studies and, more recently, advances in molecular genetics, the non-entity called essential hypertension is shrinking'. Hopefully the concerted efforts of clinicians and scientists with an interest in hypertension will result in a further erosion of this 'non-entity' in the forthcoming years. In doing so we should enter an era when antihypertensive therapy can be effectively targeted to subgroups of patients with hypertension depending upon the underlying aetiology.
